MannKind CorpMNKD
MNKD
About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Employees: 407
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
569% more call options, than puts
Call options by funds: $5.45M | Put options by funds: $815K
7% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 69
3.49% less ownership
Funds ownership: 58.06% [Q1] → 54.57% (-3.49%) [Q2]
12% less funds holding
Funds holding: 254 [Q1] → 224 (-30) [Q2]
28% less capital invested
Capital invested by funds: $887M [Q1] → $642M (-$245M) [Q2]
56% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 48
67% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 1 (-2) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
69%
upside
Avg. target
$8
94%
upside
High target
$9
118%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Douglas Miehm | 69%upside $7 | Outperform Maintained | 7 Aug 2025 |
HC Wainwright & Co. Brandon Folkes | 118%upside $9 | Buy Reiterated | 25 Jul 2025 |
Financial journalist opinion
Based on 12 articles about MNKD published over the past 30 days
Positive
Benzinga
19 hours ago
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
MannKind Corporation MNKD on Monday agreed to acquire scPharmaceuticals Inc. SCPH for a deal value of up to approximately $360 million, or $5.35 per share.
Neutral
Seeking Alpha
20 hours ago
MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Mergers and Acquisition Conference Call August 25, 2025 8:30 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
Neutral
GlobeNewsWire
1 day ago
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX ® , an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need Upfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash payment represents a 36% premium to scPharmaceuticals' 90 trading day VWAP, and total consideration of up to $6.35 per share represents up to a 31% premium to scPharmaceuticals' closing price on August 22, 2025 Strengthens organization by integrating scPharmaceuticals' established commercial and medical capabilities into MannKind's existing infrastructure FUROSCIX ReadyFlow Autoinjector on track for Q3 2025 sNDA submission, potentially unlocking additional market opportunity MannKind to host conference call today at 8:30 a.m. (ET) DANBURY, Conn.
Neutral
Seeking Alpha
2 weeks ago
MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q2 2025 Earnings Call August 6, 2025 9:00 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
Positive
Seeking Alpha
2 weeks ago
MannKind Corporation: A Post-Q2 Assessment
Today, we take another look at MannKind Corporation, which specializes in inhaled therapeutics for endocrine and orphan lung diseases, with a market cap of $1.15 billion. The company just reported second-quarter results and continues to enjoy universal support from the analyst firm community. MannKind saw decent growth from its two core products on the market in Q2 and just signed a new non-dilutive financing agreement with Blackstone.
Positive
Zacks Investment Research
2 weeks ago
MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
The Motley Fool
2 weeks ago
MannKind (MNKD) Q2 Revenue Rises 6%
MannKind (MNKD -9.52%), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from this release was a 6% increase in total revenue to $76.53 million (GAAP), primarily from royalty gains and higher Afrezza inhaled insulin sales.
Neutral
Zacks Investment Research
2 weeks ago
MannKind (MNKD) Reports Break-Even Earnings for Q2
MannKind (MNKD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.05 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
Strengthens MannKind's capital structure with flexible, long-term, non-dilutive funding MannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Neutral
GlobeNewsWire
2 weeks ago
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 YTD 2025 revenues of $154.9M, +12% v.
Charts implemented using Lightweight Charts™